The University of Oxford is set to begin a trial combining Covid-19 vaccines from AstraZeneca Plc and Pfizer Inc. that could enable greater flexibility in the use of scarce supplies globally.
The university will begin recruiting 820 participants over 50 years of age across eight U.K. sites this week, according to a statement Thursday. The Astra and Pfizer vaccines will be given in different orders and with two dosing intervals, four and 12 weeks apart.
